drug · small molecule
JOURNAVX
updated 6mo ago/ soo-ZE-tri-jeen /
by $VERX Vertex, Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying JOURNAVX
- phase3Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
- phase4A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
- phase4Suzetrigine for Non-Mastectomy Breast Surgery
- phase1Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
- phase1Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
- phase3Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
- phase3Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- phase4Evaluation of Pain Treatment After Total Knee Arthroplasty
News(10)
- Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict loomsAnalysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.biospace · 2d ago
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.biopharma_dive · 16d ago
- Drug prices climb past $250K as US patients balk at the pharmacyJust one-third of patients prescribed new medicines filled them within 30 days, with a new report from the Institute for Clinical and Economic Review and West Health suggesting that cost is the pro…biospace · 29d ago
- Most new drugs are still too costly at launch, ICER saysA new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.biopharma_dive · 1mo ago
- Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in miceWhile psychedelic drugs may be capturing all the attention when it comes to finding fresh ways to treat neuropathic pain, research with mice has suggested a peptide approach may also be effective.fiercebiotech · 1mo ago
- How J&J paved the way for Compass’ coming psychedelic drug launchIn an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Sprav…biopharma_dive · 1mo ago
- Werewolf and Ambros to tie the knot in $150M rare disease dealThe merger, which would create a new company bearing Ambros’ name, will help support development of Ambros' non-opioid painkiller for patients with debilitating limb injuries.biospace · 3mo ago
- Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: AnalystsIf confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…biospace · 3mo ago
- Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vagueAntibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.fiercebiotech · 3mo ago
- BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOsBlossomHill Therapeutics will use its $150 million IPO proceeds to power the Phase 1/2 development of a non-small cell lung cancer drug, while Latigo Therapeutics will bring in more than $345 milli…biospace · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that